Genio System 2.1
Nyxoah S.A. · Decision date Jul 30, 2026
What did the FDA approve?
FDA records P240024/S004 as a supplement to PMA P240024, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 30, 2026.
FDA approval order statement
Approval for firmware updates to the Activation Chip (AC) Model #2364 of the Genio System 2.1 with associated updates to software documentation, risk management files, and verification and validation reports.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Anesthesiology
- Decision date
- Jul 30, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P240024/S004
- Regulatory pathway
- PMA supplement
- Applicant
- Nyxoah S.A.
- Product code
- MNQ
- Decision code
- APPR
- Decision date
- Jul 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, hypoglossal nerve, implanted, apnea.
- Applicant
- Nyxoah S.A.
- Product code
- MNQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240024. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240024 · Original PMA
Genio System 2.1
P240024/S001 · Related supplement
Genio System 2.1
P240024/S002 · Related supplement
Genio System 2.1
P240024/S004 received
Application receipt date recorded by FDA.
P240024/S003 · Related supplement
Genio System 2.1
P240024/S004 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P240024. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240024
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Genio System 2.1P240024 | Nyxoah S.A. | PMA approval | Aug 8, 2025 | FDA |
Genio System 2.1P240024/S001 | Nyxoah S.A. | PMA supplement | Oct 3, 2025 | FDA |
Genio System 2.1P240024/S002 | Nyxoah S.A. | PMA supplement | Nov 6, 2025 | FDA |
Genio System 2.1P240024/S003 | Nyxoah S.A. | PMA supplement | Jun 8, 2026 | FDA |
Explore the linked device profile
Other records with product code MNQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Model 4063 Dedicated Tray SealerP130008/S148 | Inspire Medical Systems | PMA supplement | Nov 5, 2026 | FDA |
INSPIRE II UPPER AIRWAY STIMULATORP130008/S144 | Inspire Medical Systems | PMA supplement | Oct 26, 2026 | FDA |
Model 3150 IPGP130008/S147 | Inspire Medical Systems | PMA supplement | Oct 22, 2026 | FDA |
Model 3150 IPGP130008/S146 | Inspire Medical Systems | PMA supplement | Oct 13, 2026 | FDA |
INSPIRE II UPPER AIRWAY STIMULATORP130008/S123 | Inspire Medical Systems | PMA supplement | Aug 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Nyxoah S.A.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Rue Edouard Belin, 12, Mont-Saint-Guibert, 1435
Sources and methodology
- Original FDA record: P240024/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





